Use of Virtual Reality in the Reduction of Pain After the Administration of Vaccines Among Children in Primary Care Centers.
- Conditions
- PainVirtual RealityPediatricsVaccination
- Interventions
- Behavioral: Traditional DistractorsDevice: Pico G2 Virtual Reality Glasses (Pico Interactive Inc), together with an Android AOYODKG tabletBiological: Triple Viral + Varicella Vaccine at 3 years of ageBiological: Hepatitis A + Diphtheria-Tetanus-Pertussis Vaccine at 6 years of age.
- Registration Number
- NCT06313762
- Lead Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
- Brief Summary
The objective of this randomized, multicenter, open-label, parallel, controlled clinical trial is to evaluate pain reduction during the administration of two vaccines in children aged 3 and 6 years through virtual reality.
The main question\[s\] it aims to answer are:
1. To evaluate the reduction in pain during the administration of two vaccines in children aged 3 and 6 years.
2. To evaluate the reduction in anxiety during and after the administration of two vaccines in children aged 3 and 6 years.
3. Improve the satisfaction of parents or legal guardians after the administration of two vaccines in children aged 3 and 6 years.
4. Evaluate the Safety of the use of virtual reality glasses in children aged 3 and 6 years during the administration of vaccines.
The study population will include children aged 3 and 6 years who are included in the patient registry and are being seen in a primary care center of the Catalan Institute of Health in Central Catalonia.
The clinical trial has two assigned groups: a control group and an intervention group.
The intervention group will use the Pico G2 VR goggles (Pico Interactive Inc) during the administration of the two vaccines, together with an Android AOYODKG tablet, which will be connected to the goggles as a controller.
The control group participants will receive traditional distractors, such as being held by the parent or guardian who accompanies them to the appointment, receiving stickers at the end of the appointment, or receiving rewards that the parent or guardian has prepared from home.
International Registered Report Identifier (IRRID): PRR1-10.2196/35910
- Detailed Description
The participants will be selected from a patient diary register. Both the sequence and the allocation of participants to the interventions will be generated by using the RandomizedR computer system.
Due to the nature of the study, it will not be possible to mask patients or health care professionals. Therefore, the trial will be open or unblinded. However, a blind evaluation by third parties will be carried out, as the person in charge of data analysis will not be involved with the intervention.
To detect a 1-point difference between the two groups on the pain level scale, a sample of 150 boys and girls in each group is required, assuming an SD of 3 points, an α risk of 5%, a power of 80%, and an estimated loss to follow-up rate of 5%.
The data will be obtained through Microsoft Forms (anapplication included in Office 365 \[Microsoft Corporation\] that allows one to create customized questionnaires, surveys, and records) and analyzed with R software (version 4.0.3).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 300
The patients who will take part in the study will be those from the pediatric population (ie, those aged 3 and 6 years) in the register of patients from a primary care center of the Catalan Institute of Health in Central Catalonia who, according to the vaccination schedule, are due to receive 1 of the following 2 vaccinations:
- the triple viral+varicella vaccine at 3 years of age.
- the hepatitis A+diphtheria-tetanus-pertussis vaccine at age 6.
- Patients who have already received 1 of the 2 vaccines to be administered.
- Patients and accompanying persons who do not understand and speak Catalan or Spanish.
- Patients with physical or mental illnesses, as well as those with blindness or deafness.
- Patients with a known history of epileptic episodes or severe motion sickness.
- Patients with autism spectrum disorder.
- patients with any infections, burns, or injuries to the face, head, or neck that may interfere with the placement of the VR device.
- the absence of legal guardians for signing the informed consent form.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Intervention Group Hepatitis A + Diphtheria-Tetanus-Pertussis Vaccine at 6 years of age. - Control Group Traditional Distractors - Control Group Triple Viral + Varicella Vaccine at 3 years of age - Intervention Group Triple Viral + Varicella Vaccine at 3 years of age - Intervention Group Pico G2 Virtual Reality Glasses (Pico Interactive Inc), together with an Android AOYODKG tablet - Control Group Hepatitis A + Diphtheria-Tetanus-Pertussis Vaccine at 6 years of age. -
- Primary Outcome Measures
Name Time Method Evaluation of pain perception during the administration of two vaccines in children aged 3 and 6 years, through the Wong-Baker Pain Scale. Up to 24 months O: no hurt, 2: hurts little bit, 4: hurts little more, 6: hurts even more, 8: hurts whole lot, 10: hurts worst
- Secondary Outcome Measures
Name Time Method Degree of satisfaction of parents/legal guardians of minors after the administration of two vaccines, using the CSAT scale. Up to 24 months Not at all satisfied, slightly satisfied, normal, satisfied, very satisfied.
Evaluation of anxiety during the administration of two vaccines in children aged 3 and 6 years, through heart rate and the Children's Fear Scale. Up to 24 months 0: no anxiety, 1: mild anxiety, 2: moderate anxiety, 3: severe anxiety, 4: very severe anxiety
Number of patients who experienced adverse effects during the administration of vaccines and who used virtual reality glasses, through the registration of the effects presented. Up to 24 months Record of adverse effects: None, fall, seizures, loss of consciousness, blurred vision, dizziness, nausea, headache, others.
Trial Locations
- Locations (1)
Catalan Institute of Health. Territorial Management of Central Catalonia.
🇪🇸Manresa, Barcelona, Spain